Panagora Asset Management Inc. holds $397,000 position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Panagora Asset Management Inc. acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 17,748 shares of the company’s stock, valued at approximately $397,000.

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. raised its stake in Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the period. First Horizon Advisors Inc. grew its position in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares during the period. GAMMA Investing LLC boosted its stake in Intellia Therapeutics by 1,322.0% in the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after purchasing an additional 2,459 shares in the last quarter. EntryPoint Capital LLC boosted its stake in Intellia Therapeutics by 61.1% in the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares in the last quarter. Finally, AdvisorNet Financial Inc raised its holdings in Intellia Therapeutics by 63.5% during the second quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock valued at $114,000 after buying an additional 1,980 shares during the period. 88.77% of shares are owned by institutional investors and hedge funds.

Analyst upgrades and downgrades

A number of equities analysts recently weighed in on NTLA shares. Royal Bank of Canada reduced their price target on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. JPMorgan Chase & Co. cut their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Citigroup cut their price target on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.58, based on data from MarketBeat.

See our latest research report on Intellia Therapeutics

Intellia Therapeutics trading down 3.7%

Shares of NTLA stock opened at $21.62 on Wednesday. The company’s fifty day moving average price is $23.75 and its two hundred day moving average price is $24.84. Intellia Therapeutics, Inc. has a one year low of $19.37 and a one year high of $38.71. The firm has a market cap of $2.09 billion, a P/E ratio of -4.03 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA – Get Your Free Report ) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. During the same period last year, the firm earned ($1.40) EPS. Intellia Therapeutics’s quarterly revenue was down 48.5% compared to the same quarter last year. As a group, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Intellia Therapeutics Profile

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on developing curative therapies. The company’s in vivo programs include NTLA-2001, which is in a Phase 1 clinical trial for the treatment of amyloidosis with transthyretin; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for lung disease associated with alpha-1 antitrypsin deficiency.

Recommended articles

Want to see what other hedge funds NTLA owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report).

Get news and reviews for Intellia Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intellia Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.